Tesaro Reports Positive Phase III Results For Opko Nausea Drug

– The Adverse Event Profile for Rolapitant was Consistent with Earlier Clinical Trials. Preparations Continue in Support of Submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration More...